News
IPSC
2.020
-1.94%
-0.040
Century Therapeutics Reports Q2 Results, Pipeline Advancements
TipRanks · 4h ago
Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate
Benzinga · 5h ago
Century Therapeutics GAAP EPS of -$0.17 misses by $0.05
Seeking Alpha · 5h ago
*Century Therapeutics 2Q Loss/Shr 17c >IPSC
Dow Jones · 5h ago
*Century Therapeutics 2Q Rev $0.00 >IPSC
Dow Jones · 5h ago
Press Release: Century Therapeutics Reports -2-
Dow Jones · 5h ago
Press Release: Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Dow Jones · 5h ago
Weekly Report: what happened at IPSC last week (0803-0807)?
Weekly Report · 2d ago
Weekly Report: what happened at IPSC last week (0727-0731)?
Weekly Report · 08/03 09:15
Weekly Report: what happened at IPSC last week (0720-0724)?
Weekly Report · 07/27 09:16
Weekly Report: what happened at IPSC last week (0713-0717)?
Weekly Report · 07/20 09:15
Weekly Report: what happened at IPSC last week (0706-0710)?
Weekly Report · 07/13 09:16
Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential
Seeking Alpha · 07/09 17:41
Weekly Report: what happened at IPSC last week (0629-0703)?
Weekly Report · 07/06 09:16
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 06/30 12:03
Weekly Report: what happened at IPSC last week (0622-0626)?
Weekly Report · 06/29 09:15
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Benzinga · 06/26 14:18
Weekly Report: what happened at IPSC last week (0615-0619)?
Weekly Report · 06/22 09:17
Weekly Report: what happened at IPSC last week (0608-0612)?
Weekly Report · 06/15 09:17
Century Therapeutics Shareholders Approve Directors and Share Increase
TipRanks · 06/12 21:03
More
Webull provides a variety of real-time IPSC stock news. You can receive the latest news about Century Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.